Oppenheimer & Co’s Inovio Pharmaceuticals INO Stock Holding History

Oppenheimer & Co’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,862	Closed	-$209K	–	1474
2022 Q1	$209K	Buy	4,862 +2,842	+141%	+$128K	﹤0.01%	1337
2021 Q4	$121K	Buy	+2,020	New	+$162K	﹤0.01%	1434
2021 Q3	–	Sell	-1,026	Closed	-$114K	–	1532
2021 Q2	$114K	Buy	+1,026	New	+$98.5K	﹤0.01%	1466

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Oppenheimer & Co's INO Position: Q2 2022 in Review

Oppenheimer & Co sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 4,862 shares — an estimated $209K sold.

Oppenheimer & Co first reported a position in INO in Q2 2021 and held it in 3 quarters. The position peaked at $209K in Q1 2022. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

Oppenheimer & Co reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Oppenheimer & Co sold 4,862 Inovio Pharmaceuticals shares in Q2 2022, an estimated $209K.
Oppenheimer & Co first reported a position in Inovio Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Oppenheimer & Co's Inovio Pharmaceuticals position peaked at $209K in Q1 2022.
184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Oppenheimer & Co's 13F filing for Q2 2022, filed 8 Aug 2022.